Pharmacokinetic-Pharmacodynamic (PK/PD) Modeling (5-day) Training
Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
---|---|
State: | Federal |
Level of Government: | Federal |
Category: |
|
Opps ID: | NBD00159410226883770 |
Posted Date: | Apr 16, 2024 |
Due Date: | May 2, 2024 |
Solicitation No: | 75F40124R00072 |
Source: | Members Only |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Combined Synopsis/Solicitation (Original)
- All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
- Original Published Date: Apr 16, 2024 03:41 pm EDT
- Original Date Offers Due: May 02, 2024 10:00 am EDT
- Inactive Policy: 15 days after date offers due
- Original Inactive Date: May 17, 2024
-
Initiative:
- None
- Original Set Aside: Total Small Business Set-Aside (FAR 19.5)
- Product Service Code: U099 - EDUCATION/TRAINING- OTHER
-
NAICS Code:
- 541690 - Other Scientific and Technical Consulting Services
-
Place of Performance:
AFG
The purpose of this requirement is to increase OB scientist and technical staff’s knowledge, skills, and abilities to perform their duties in working at the drug discovery interface responsible for lead optimization and candidate selection thereby aiding OB in serving FDA’s mission. Current approaches in the field of Pharmacokinetic-Pharmacodynamic involve development of models based on mechanisms of drug action and their alteration of physiologic processes. This course will provide a comprehensive overview of the principles, techniques, and applications of PK/PD modeling with a partial emphasis on modeling for bioequivalence (BE) assessment. Such modeling allows the optimal design and interpretation of pharmacologic experiments that range from molecular biology to human responses and can expedite the drug development process. Lectures and examples from the literature will be provided with course notes for all participants. Selected models or examples will include computer code to show how to quantitate typical experimental data. At the conclusion of this course, the biomedical scientist with basic knowledge in pharmacokinetic will be able to understand the diverse array of available PK/PD models and begin to apply them to experimental data and simulate anticipated drug responses.
Specific topics that will be considered in this training include the following:
-
- Modeling and simulation of modified release solid oral products to ensure the consistency and quality of BE recommendations.
- Modeling and simulation to reduce/replace in vivo BE studies (i.e. in vivo PK BE studies, clinical endpoint or pharmacodynamic endpoint BE studies) for complex generic products and other generic products with clinical study challenges including long acting injectable and implantable products, oncology drug products, and orphan drug products.
- PK/PD modeling of narrow therapeutic index drugs and complex drug products and clinical trial simulations to aid risk-based BE evaluation.
- PK/PD modeling and simulation to determine the appropriate study design and evaluate sensitivity for BE assessment.
- 4041 Powder Mill Road 4th Floor
- Beltsville , MD 20705
- USA
- Pamela T. Lee
- pamela.lee@fda.hhs.gov
- Phone Number 2404023847
- Janice Heard
- janice.heard@fda.hhs.gov
- Phone Number 215-717-3093
- Apr 16, 2024 03:41 pm EDTCombined Synopsis/Solicitation (Original)
TRY FOR FREE
Not a USAOPPS Member Yet?
Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.